Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced that it has entered into a Settlement Agreement with Ranbaxy Inc. to dismiss, without prejudice, its patent infringement action pending against Ranbaxy in the United States District Court for the District of Delaware. In the suit, Acura alleges that a generic of Acura’s AVERSION® oxycodone product, previously marketed by Pfizer Inc. under its brand name OXECTA®, for which Ranbaxy is seeking approval to market in the United States pursuant to an Abbreviated New Drug Application (ANDA) filing with the U.S. Food and Drug Administration (FDA) infringes U.S. patents owned by Acura. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) weekly performance is -0.81%. On last trading day company shares ended up $1.22. Analysts mean target price for the company is $2.25. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) distance from 50-day simple moving average (SMA50) is -15.51%.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) entered into a convertible promissory note (the “Note”) with Robert Noel Robinson (the “Lender”) in an aggregate principal amount of $600,000. The Note was initially convertible into shares of the Company’s common stock at any time at the discretion of the Lender at an initial conversion price per share of $9.35, giving effect to the Company’s 1-for-17 reverse stock split of the outstanding common stock effected in December 2013. Effective June 25, 2013, the Company and the Lender entered into a Consent, Waiver and Amendment Regarding Convertible Promissory Note which, among other things, amended the maturity date of the Note to be March 26, 2014. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) shares fell -3.28% in last trading session and ended the day on $ 6.79. Its return on assets is -259.60%. Adamis Pharmaceuticals Corp (NASDAQ:ADMP) quarterly performance is 7.10%.
Alkermes plc (NASDAQ:ALKS) announced that its corporate presentation will be webcast live at the UBS Global Healthcare Conference on Monday, May 19, 2014, at 8:30 a.m. EDT (1:30 p.m. BST) from the Sheraton New York Hotel. The presentation may be accessed under the Investors tab onwww.alkermes.com and will be archived for 14 days. Alkermes Plc (NASDAQ:ALKS) shares moved down -0.98% in last trading session and was closed at $43.59, while trading in range of $43.16 – $44.97. Alkermes Plc (NASDAQ:ALKS) year to date (YTD) performance is 7.21%.
Bio-Path Holdings, Inc (NASDAQ:BPTH) a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, announced operational and financial results for the first quarter ended March 31, 2014. The Company reported a net loss of $504,876 for the three month period ended March 31, 2014, compared to a net loss of $656,002 for the three month period ended March 31, 2013. The decrease was due to research and development expenses being lower in the quarter ended March 31, 2014 due to lower drug material and clinical trial expenses, offset to some extent by higher general and administrative expense. The increased general and administrative expense was primarily due to the exchange listing fee for the Company’s common stock to be listed on the NASDAQ Capital Market and non-cash expense from vesting of previously granted stock options to officers, directors and management. Bio-Path Holdings Inc (NASDAQ:BPTH) ended the last trading day at $2.70. Company weekly volatility is calculated as 4.23% and price to cash ratio as 66.92. Bio-Path Holdings Inc (NASDAQ:BPTH) showed a positive weekly performance of 1.89%.